The ACTN4 Knockout HeLa Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of HeLa cells with targeted disruption of the ACTN4 gene. This heterogeneous knockout model provides a loss-of-function system for studying ACTN4-dependent phenotypes at the population level, avoiding clonal selection artifacts. The polyclonal format is ideal for experiments requiring robust, reproducible results in cell migration, adhesion, and signaling studies, and can be validated by techniques such as Western blotting.
HeLa cells, derived from an HPV18-positive cervical adenocarcinoma, are immortalized epithelial cells widely employed in cancer research. Their transformed character and well-documented signaling pathways make them a versatile host for studying tumor cell behavior, including cytoskeletal dynamics and metastatic properties. Introducing the ACTN4 knockout into this background provides a direct platform to assess gene function in a physiologically relevant epithelial cancer context.
ACTN4 (??-actinin-4) crosslinks actin filaments and is a component of focal adhesions, where it interacts with vinculin, integrin ??1, and FAK to regulate adhesion turnover. The protein is activated by TGF-??, Wnt, and PI3K-Akt signaling in response to mechanical tension. Additionally, ACTN4 translocates to the nucleus and functions as a coactivator for transcription factors including NF-??B, YAP/TAZ, and ??-catenin, thereby promoting expression of genes that facilitate cell migration and invasion. ACTN4 also interacts with scaffold proteins such as PDLIM1 and MAGI1, linking the cytoskeleton to signaling complexes.
In the HeLa ACTN4 knockout model, disruption of actin crosslinking and focal adhesion dynamics permits detailed dissection of mechanisms underlying cancer cell motility and metastasis. The model is particularly powerful for examining crosstalk between the Hippo/YAP and Wnt/??-catenin pathways, given HeLa??s active signaling. It is also relevant to research on focal segmental glomerulosclerosis, where ACTN4 mutations cause podocyte dysfunction, and to studies of drug resistance in breast, colorectal, and lung cancers, where elevated ACTN4 is associated with poor outcomes.
Key research applications include Transwell migration and invasion assays, wound healing assays, and immunofluorescence staining for F-actin and focal adhesion markers. Co-immunoprecipitation can map interactions between ACTN4 and partners like FAK or vinculin, while phospho-kinase profiling reveals altered signaling networks. RNA-seq analyses of knockout versus wild-type cells identify ACTN4-dependent transcriptional programs. The cells also support drug screening focused on PI3K-Akt or TGF-?? pathways. For additional details, contact Ascent Research.
